OSIP-486823 (OSIP 486823) (Synonyms: OSIP 486823; OSIP486823; CP248) |
Catalog No.GC33163 |
OSIP-486823 (OSIP 486823) es un nuevo agente que interfiere en los microtÚbulos con distintos efectos biolÓgicos tanto en la proteÍna quinasa G (PKG) como en los microtÚbulos.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 200803-37-8
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: | The SW480 human colon adenocarcinoma and NIH3T3 mouse fibroblast cell lines are seeded in six-well plates at a density of 3×104 per well, grown for 36 to 48 hours, and then exposed to increasing concentrations of each compound (e.g., OSIP-486823; 1, 2 and 4 μM) for 48 hours. Cell numbers are determined using a Coulter counter and results are expressed as a percentage of the control culture. All assays are done in triplicate. Data are analyzed in Excel and the IC50s are determined graphically from cell survival curves[1]. |
References: [1]. Xiao D, et al. The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization. Mol Cancer Ther. 2006 Jan;5(1):60-7. |
OSIP-486823 is a novel microtubule-interfering agent with distinct biological effects on both protein kinase G (PKG) and microtubules.
OSIP486823 inhibits growth and induce apoptosis in SW480 human colon cancer cells, with IC50 of 0.1 μM. OSIP-486823 (OSIP486823) causes depolymerization of microtubules in interphase cells, inhibit spindle formation in mitotic cells, and induce multinucleated cells. Exisulind and the potent synthetic derivative OSIP-486823 are members of a new class of drugs known as selective apoptotic antineoplastic drugs that target cyclic guanosine 3′,5′-monophosphate phosphodiesterases (cGMP-PDE). OSIP-486823 also disrupts microtubule polymerization, perturbs mitotic spindle function, and arrests cells in mitosis in human glioma cells[1].
[1]. Xiao D, et al. The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization. Mol Cancer Ther. 2006 Jan;5(1):60-7.
Cas No. | 200803-37-8 | SDF | |
Sinónimos | OSIP 486823; OSIP486823; CP248 | ||
Canonical SMILES | O=C(NCC1=CC=CC=C1)CC(C2=C/3C=CC(F)=C2)=C(C)C3=C\C4=CC(OC)=C(OC)C(OC)=C4 | ||
Formula | C29H28FNO4 | M.Wt | 473.54 |
Solubility | Soluble in DMSO | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.1118 mL | 10.5588 mL | 21.1175 mL |
5 mM | 0.4224 mL | 2.1118 mL | 4.2235 mL |
10 mM | 0.2112 mL | 1.0559 mL | 2.1118 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 39 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *